NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Aug. 23, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain purchasers of shares of Avinger Inc (NASDAQ:AVGR) over alleged violations of Federal Securities Laws by Avinger Inc in connection with Avinger’s initial public offering (“IPO”).
Investors, who purchased shares of Avinger Inc (NASDAQ:AVGR), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that the IPO Registration Statement and Prospectus materially and falsely failed to disclose that Avinger lacked adequate personnel to increase sales of its lumivascular-platform products and to commercialize Pantheris, that Avinger experienced problems with the robustness of its lumivascular-platform devices (including Pantheris), that physicians and hospitals were requiring more extensive training concerning Avinger’s products as compared to competing products, that Avinger would not be able to rapidly ramp up sales of its lumivascular platform, and that as a result, Avinger experienced lower than expected sales and revenues.
Those who purchased Avinger Inc (NASDAQ:AVGR) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
